Merck Serono LTD, Israel

Progestogen. Progesterone 8% w/w.
Sgle. use prefill. vag. gel applic.:6,15 X1.125 g. Infert. due to inad. luteal phase: 1 applic/day start. after docum. ovul. or arbitr. on the 18^th-21^st-day of the cycle. For in- vitro fertil., when infertil. is due to tubal, idiopathic or endometriosis linked steril. assoc. with normal cycles: 1 app/day for 30 days if there is lab evid. of pregn. Infert. due to inadeq. luteal phase. In- vitro fertil., when infertil. is due to tubal, idiopathic,or endometriosis linked steril. assoc. with normal cycles.
C/I:Hypersens, Undiagn. vag. bleeding. Known or susp. progest.-sensit. malign. tumors. Porphyria. Thrombophleb., thromboembolic dis, cereb. apoplexy, or pts. with an history of these condit. Missed abort.

Biguanide. Metformin Hydrochloride 500 mg, 700 mg, 1000 mg.
XR tab 30/60/90/120 X 500/750/1000 mg
Diabetes reduct. of risk or delay: ther. should be initiated with 500 mg once/d with the evening meal. • After 10 to 15 days, dose adjust. on the basis of blood glucose measurm. is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow incr. of dose may improve GI tolerability. Max. dose is 2000 mg once/d with the evening meal.
Monother. in Type 2 diabetes mellitus and combin. with other oral antidiabetic agents: usual starting dose is 500 mg once/d. • After 10 to 15 days the dose should be adjusted on the basis of blood glucose measur. A slow incr. of dose may improve GI tolerability. Max. recomm. dose is 2000  mg /d. • Dosage incr. should be made in increm. of 500 mg every 10-15 days, up to a max. of 2000 mg once/d with the evening meal. If glycaemic ctrol is not achieved on 2000 mg once/d, 1000 mg twice/d should be considered, with both doses being given with food. If glycaemic ctrol is still not achieved, pts. may be switched to standard metformin tabs. to a max. dose of 2550 mg daily. See full prescr. info.

• Reduction in risk or delay of onset of type 2 diabetes mellitus in adult, overweight pts with IGT* and/or IFG*, and/or increased HbA1C who are:- at high risk for developing overt type 2 diabetes mellitus and- still progressing towards type 2 diabetes mellitus despite implement. of intensive lifestyle change for 3 to 6 months.Tmt. must be based on a risk score incorporating appropriate measures of glycaemic ctrol. and including evidence of high CV risk. Lifestyle modif.  should be continued when metformin is initiated, unless  ptt is unable to do so because of med. reasons.*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose
• Tmt of type 2 diabetes mellitus in adults, particularly in overweight ptts, when dietary management and exercise alone does not result in adeq. glycaemic ctrol. May be used as monother. or in combin. with other oral antidiabetic agents, or with insulin.
C/I: Hypersens. •  Any type of acute metabolic acidosis • Diabetic pre-coma • Sev. renal failure (GFR < 30 mL/min). • Acute condit. with the potent. to alter renal function such as: - dehydrat, - severe infect, - shock. • Dis. which may cause tissue hypoxia (especially acute dis., or worsening of chron. dis.) such as: - decompensated HF, - respir. failure, - recent MC infarction, - shock. • Hepatic insuf., acute alcohol intox., alcoholism.

Immunosuppressant. Cladribine 10 mg.
Tab: 1/4/6X 10 mg: 3.5 mg/kg bw over 2 years,  admin. as 1 tmt. course of 1.75 mg/kg per year. Tmt. course consists of 2 tmt. weeks, one at the beginn. of the first month and one at the beginn. of the sec. month of the respect. tmt. year. See prescr. info.
Tmt. of adlt. pts. with high. act. relaps. multiple sclerosis (MS) as by clinical or imaging features
C/I: Hypersens.
HIV.
Act. chron. infect. (tuberculosis or hepatitis).
Init. of this tmt. in immunocomprom. pts, incl. pts. on
immunosuppr. or myelosuppr. ther. (See prescr. info).
Act. malign.
Mod. or sev. renal impair. (creat. clear. <60 mL/min) (See prescr. info).
Pregn. and breast-feed.

Protein Kinase Inhibitor. Tepotinib (as hydrochloride hydrate) 225 mg.
FC tabs:60 Two tabs, once/day
Tmt. of adlt pts. with metastatic non-small cell lung
cancer (NSCLC) harbouring a MET tyrosine kinase receptor exon 14 (METex14) skip. mut.
C/I:Hypersens., see prescr. info. for full details.